



**SAMANTHA DICKSON
BRAIN TUMOUR TRUST**

Head to head with brain tumours

**SAMANTHA DICKSON BRAIN TUMOUR TRUST
(COMPANY LIMITED BY GUARANTEE)**

**ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 March 2010**

Registered charity no. 1128354

Company registration no. 05615995

Index

Page

2	Trust Information
3	Report of the Trustees
8	Statement of the Trustees' Responsibilities
9	Independent Auditor's Report
11	Statement of Financial Activities
12	Balance Sheet
13	Notes to the Financial Statements

Reference and Administrative Information

Trustees

Mr Neil A Dickson (Chairman)
Mr Graham Norton (Vice Chair)
Mrs Angela J Dickson
Dr Ian Woods (resigned April 09)
Mr Peter G McDermott
Mrs Berendina Norton
Mr Ian Andrew (resigned April 09)
Dr Alistair Nunn
Lady Alison Wakeham
Ms Philippa Murray
Mr Peter Unsworth (appointed November 2009)
Mr Gavin St Pier (appointed November 2009)
Mr Andrew Silver (appointed November 2009, resigned September 2010)
Ms Ann Gales (appointed November 2009)
Mrs Shirley Barnfield (appointed November 2009)
Mr Aidan Lisser (appointed November 2009)

Chief Executive Officer and Company Secretary

Mr Paul Carbury

Registered Charity Number: 1128354

Registered Company Number: 05615955

Principal Office

Saddlers House
100 Reading Road
Yateley
Hampshire GU46 7RX

Auditors

Haysmacintyre
Fairfax House
15 Fulwood Place
London
WC1V 6AY

Legal Advisors

Bates, Wells and Braithwaite LLP
Scandinavian House
2 - 6 Canon Street
London
EC4M 6YH

Bankers

Lloyds Bank Plc
174 Fleet Road, Fleet
Hampshire
GU13 8DD

Bank of Scotland
Buchan House, Parkway Court
Oxford Business Park
Oxford OX4 2JY

CCLA Investment Management Ltd
COIF Charity Funds
80 Cheapside
London
EC2V 6DZ

Report of the Trustees

The trustees, who are also directors of the charity for the purpose of Companies Act, present their annual report and financial statements of the charity for the year ended 31 March 2010. The Trustees confirm that the annual report and financial statements of the charitable company comply with current statutory requirements, the requirements of the charity's governing document and the provisions of the Statement of Recommended Practice (SORP) 'Accounting and Reporting by charities' issued in 2005.

The trustees confirm that they have complied with the duty in section 4 of the Charities Act 2006 to have due regard to the public benefit guidance published by the Charity Commission in determining the activities undertaken by the charity.

Structure, Governance and Management

Samantha Dickson Brain Tumour Trust is a registered charity, number 1128354, which was incorporated on 8th November 2005 and is governed by its memorandum and articles of association.

The Trustees with the advice of their solicitors Bates, Wells and Braithwaite's decided to restructure the organisation of the charity by changing the constitution from a Trust to a company limited by guarantee. The company has registered as a charity on the 3 March 2009.

The assets, liabilities and ongoing contracted obligations of the Trust were deemed to have transferred to the company as at 1 April 2009 with the legal agreement being signed on 22 May 2009. An existing dormant company was used for this purpose. The comparative figures included in the financial statements relate to the old Trust, Charity number 1060627.

The trustees who served during the year are set out on Page 2. Trustees are appointed by a resolution passed at a meeting called by the Chairman and any two trustees. During the year, two trustees, Dr Ian Woods and Mr Ian Andrew, resigned – we thank them for their time, support and contribution throughout the previous years.

Six new trustees were appointed; together they bring a wealth of experience from the commercial, marketing and financial sector and will be a tremendous asset to help the charity grow and develop. Following their appointment, new trustees go through an induction process which includes meeting the Chair and Senior Staff and an induction pack including the Trust's business plan and other relevant information. One of the new trustees, Andrew Silver, has since stepped down for personal reasons and continues to support the Trust in other ways.

The trustees meet at least four times per year and agree the broad strategy and areas of activity for the Trust including research strategy, approval of research grants, patient support strategy, financial planning, investment, reserves and risk management policies and performance.

All trustees give of their time freely and no trustee remuneration was paid in the year. Details of trustee expenses are disclosed in Note 6 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and in accordance with the Trust's policy withdraw from decisions where a conflict of interest arises.

Day to day operations and management are delegated to the Chief Executive and Senior Management Team who provide regular reports to the trustees on performance and operations.

The Trust also benefits from four sub-committees which have been established to advise on key areas of activity. These are:

- Finance and Audit Sub-Committee
- Research Sub-Committee
- Patient Support Sub-Committee
- Grant Review and Monitoring Committee

The Trust was supported during the year by over 300 international reviewers from around the world who undertook peer review assessments of research grant applications and made recommendations to the Grant Review and Monitoring Committee (GRAM).

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010

The GRAM is made up of twelve international brain tumour and cancer specialists and two lay people personally affected by brain cancer. The GRAM assesses peer reviewers scores and comments on grant applications and advises the Board of Trustees on the scientific merit of each proposal so informed funding decisions can be made. This process enables Trustees to select only the most high quality research projects for funding. GRAM members give their time for free, and we are extremely grateful to them for their contribution to our work. The GRAM is made up of the following members:

Name	Institution/lay member
Dame Ingrid Allen (Chair)	Queens University Belfast
Professor Jillian Birch	University of Manchester
Professor Steven Clifford	University of Newcastle
Professor V Peter Collins	Cambridge University
Dr Stephen Falk	Bristol Oncology Centre
Dr Michelle Garrett	Institute of Cancer Research (in partnership with Royal Marsden NHS Foundation Trust)
Dr Jacques Grill	Institut Gustave Roussy, France
Mr Steven Jones	Lay member
Dr John Mason	University of Edinburgh
Professor Monica Nistér	Karolinska Institutet, Sweden
Mrs Clare Normand	Lay member
Professor Roy Rampling	Glasgow and Western Infirmary
Professor Richard Wise	Cardiff University

Umbrella groups also remain an integral part of the Trust and are at the heart of what we do. Families and friends who have lost either a loved one to a brain tumour or where a loved one is recovering from or is living with a brain tumour start umbrella groups. We have 73 umbrella groups across the UK and in the past year they have raised nearly 25% of the Trust's overall income which is a tremendous achievement.

Umbrella groups are also entirely volunteer led and put in thousands of voluntary hours each year to raise much needed awareness and funds for brain tumour research and patient support.

The Trust is a longstanding member of the Association of Medical Research Charities (AMRC). The AMRC is an umbrella organisation of the leading medical and health research charities in the UK. The Trust aims to follow the highest standards of accountability in medical and health research funding, and membership of AMRC requires the use of independent peer review in the allocation of all grants and awards for research. The Trust has received a best practice award for its peer review process.

The Trust is also a member of the Fundraising Standards Board and is represented on a number of influential bodies and cancer campaigning groups.

The Chief Executive is a member of the Association of Chief Executives of Voluntary Organisations (ACEVO) and the Institute of Fundraising.

Risk Assessment

The trustees have considered the major risks to which the charity is exposed and have reviewed those risks and established systems and procedures to manage those risks. The Finance and Audit Sub-Committee review governance and risk on a quarterly basis and make recommendations on best practice to the trustees.

Aims and Objectives

The charitable objects of the company are:

- To promote research into the causes and treatment of brain cancer with particular reference to childhood brain tumours on terms that the results of such research are published
- The relief of sufferers of brain cancer by providing support services to them and their families

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010

The Trust's objectives are achieved by awarding research grants to scientific institutions and offering practical support to patients and carers through a telephone helpline, a programme of patient centred events and provision of information.

In March 2008 the trustees agreed a business plan to 2011 in order to achieve our charitable aims and set seven goals to monitor our performance in pursuit of our objectives.

The seven strategic goals as outlined in our business plan are:

- To provide more opportunities for prevention, early diagnosis and better treatment by establishing the Samantha Dickson Brain Cancer Unit at UCL Cancer Institute
- To improve the quality of life and survival rates of people with brain cancer by funding a portfolio of new research projects and publishing research from existing projects
- To increase the number of specialists working in the brain cancer field
- To reduce the inequities in treatments for patients by funding and campaigning for an increase in clinical trials
- To expand our patient support service to reach out and help more brain tumour patients and develop and improve our services
- To raise the public's awareness and perception of our work
- To develop our infrastructure and fundraising potential

The day-to-day functions and activities of the Trust are structured to contribute to the performance and achievement of our aims and objectives, these are:

- Awarding research grants to fund leading edge brain tumour research
- A patient support helpline, information events across the UK and skilled staff to provide practical and emotional support to patients and families
- Fundraising activities to support the research and patient support functions
- Marketing and communications to raise awareness of brain tumours and to reach out to more beneficiaries
- Governance and administration to ensure effective stewardship of the organisation

Grant Making Policy

The Trust has established its grant making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

Approximately 8,500 people are diagnosed with a primary brain tumour each year and 3,500 sadly lose their lives. Brain cancer is now the biggest killer of children under 15 and young adults under 40 than any other cancer. Increasingly there are thousands of people who are diagnosed with a secondary brain tumour, where the cancer has spread from other parts of the body.

The beneficiaries of our grant making programme are ultimately people with brain tumours and their families and carers. We believe that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Trust invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. The Trust is a member of the Association of Medical Research Charities and seeks to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research and continuation of the grants is subject to annual assessment by our Research Sub-Committee and Grant Review and Monitoring Committee supported by the Head of Research. In all cases, continuation of funding is subject to the research undertaken being in the interests of the Trust and a progress assessment that is satisfactory.

Achievements and Performance

During 2009/10 we increased our income to over £1.4 million, a record year for fundraising and invested £1.13 million in our research and patient support programmes.

The Trust makes a unique contribution to the brain tumour community and the highlights in the past year include:

- Invested nearly £1 million in our brain tumour research programme in 17 projects helping to increase our understanding of the disease
- Committed the first tranche of £335,000 to fund research at our flagship centre, the Samantha Dickson Brain Cancer Unit at UCL Cancer Institute
- Undertook an independent review of the research being developed at the Samantha Dickson Brain Cancer Unit which reported that excellent progress was being made
- Funded 20 leading scientists across the UK
- Celebrated and surpassed the £5 million milestone in research funding awards
- Successfully organised a new round of research grants funding and we committed an additional £600k in research
- Established the Grant Review and Monitoring Committee made up of leading scientists to assess and review grant applications
- In partnership with the Children's Brain Tumour Research Centre and Royal College of Paediatrics and Child Health secured £380,000 to support GPs and other health professionals to reduce the time it takes for childhood brain tumours to be diagnosed
- Established other major funding partnerships with Cancer Research UK and GlaxoSmithKline to improve outcomes for children and adults with brain tumours through our research programme
- Awarded a best practice certificate from the Association of Medical Research Charities for our peer review process
- Increased our investment in patient support from £157,842 to £189,432 enabling us to support more people with brain tumours and their families
- Supported 1,000 families through our national telephone helpline and patient events programme
- Piloted a programme of information events across the UK attended by nearly 400 people with brain tumours and their carers/families – we have plans to expand this to other areas throughout the country
- Set up a specialist support service for families who are caring for children with brain tumours
- Ran a successful BBC Lifeline Appeal that was watched by 1.2 million viewers and raised £10,000
- Raised significant awareness of brain tumours via national and local media

Finance Review

Incoming resources for the year were £1,410,370 compared with £1,304,914 in the previous year. Expenditure for the year was £1,436,515 compared with £2,062,311 in the previous year.

During the year we added a number of new research grants to our portfolio which will see us invest £1,733,679 over the next 3 years in much needed brain tumour research.

The reserves policy of the charity is to maintain unrestricted funds equal to three months operational costs which at present level is £178,724. The present level of free reserves of £439,802 is made up of total reserves less restricted funds, designated funds and net book value of assets (2009 - £258,378). Trustees designated funds previously held in the general funds to fund patient support information days.

Funds are held in high interest deposit accounts and these are reviewed by the Finance and Audit Sub-Committee on a quarterly basis.

Fundraising

Families and friends who have been affected by a brain tumour generate the majority of the Trust's fundraising income (65%). In particular, our Umbrella Groups who are raising funds mostly in memory of a loved one, contributed 25% of the Trust's income. This is a tremendous achievement and our heartfelt thanks go out to all those who work tirelessly for the cause.

The remaining funds are given by generous donations from trusts, foundations and corporate supporters and we are very grateful for this continued support. During the year investment income was £15,730.

Scientific and Medical Advisory Board

In addition to the GRAM the Trust continues to be supported by its Scientific and Medical Advisory Board (SMAB) which advises on research policy, undertakes peer review assessments of research grant applications and provides a valuable resource on the latest developments in brain tumour research. The SMAB is made up of the following members:

UK Members

Rachel MacArthur	Clinical Nurse Specialist, King's College Hospital, London
Prof Dame Ingrid Allen	MB Bch BAO DSc, Queen's University, Belfast
Prof Geoffrey J Pilkington	BSc PhD CBiol FRCPATH, University of Portsmouth
Prof John L Darling	BSc MSc PhD, University of Wolverhampton
Prof Mike Brada	BSc FRCP FRCR, Royal Marsden Hospital, Sutton
Dr Janice Royds	BSc PhD, University of Sheffield Medical School
Prof Ian R Whittle	MD PhD, Western General Hospital, Edinburgh
Prof Patricia A McKinney	BSc PhD, University of Leeds
Prof V Peter Collins	MD FRCPATH, Addenbrooke's Hospital, Cambridge
Prof David A Walker	BmedSci BM BS FRCP FRCPCh, Queen's Medical Centre, Nottingham
Dr Jeremy Rees	BSc MB BS FRCP PhD, University College London
Prof Roy Rampling	PhD FRCR FRCP, Western Infirmary, Glasgow
Prof P Lantos	MD PhD DSc AcadMed.Sci FRCPATH, University of Bristol
Dr David Levy	BSc FRCR FRCP, Weston Park Hospital, Sheffield
Dr Antony Michalski	MB ChB PhD MRCP, Great Ormond Street Hospital, London
Prof Steven Clifford	MD PhD, University of Newcastle
Dr Lynn Kilbride	PhD, Napier University, Edinburgh

European Members

Prof Zvi Ram	Tel Aviv Medical Centre, Israel
Prof Roger Stupp	MD, University of Vaudois, Switzerland
Prof Dr Jorg-Christian Tonn	University of Munich, Germany
Prof Bengt Westermark	University of Uppsala, Sweden
Dr John G Wolbers	Erasmus University, Netherlands
Dr Jiri Ehrmann	MD PhD, Palacky University, Czech Republic
Prof MJ van de Bent	MD, University Medical Centre Rotterdam, Netherlands
Prof Rolf Bjerkvig	University of Bergen, Norway
Prof Monica Nister	Karolinska Institutet, Sweden

Patrons

We would also like to pay a special thank you to our many patrons and during the year Jonny Wilkinson, Alastair Stewart, Fiona Fullerton and Earl Spencer also very kindly made public appearances on behalf of the Trust. Our other patrons are as follows:

Dawn French; Chris de Burgh; Julia Somerville; Stephen Hendry; Sandy Lyle; Sir Thomas Lighton; Michael Crawford; Dame Helen Mirren; Leslie Thomas; Twiggy Lawson; Delia Smith; Martin Amis; Hayley Mills; Ciara Jansen; Tom Daley; Shamus Cullen; Christopher Bailey and Gayle McDermott.

Plans for the Future

Samantha Dickson Brain Tumour Trust is the UK's biggest brain tumour charity and its leading funder of brain tumour research. For 2010/11 the trustees have set some over-arching priorities that will help us achieve our charitable and business plan objectives. These are:

- Continue our significant investment in research and patient support programmes
- Commit the second instalment of £375,498 at the Samantha Dickson Brain Cancer Unit at UCL Cancer Institute
- Fund clinical trials in our partnership with Cancer Research UK
- Set up and deliver the Brain Cancer Care Project funded by a Big Lottery Fund grant of £236,977 which will support more brain tumour patients and their families over the next three years
- Deliver the next stage of the childhood early diagnosis project in partnership with Royal College of Paediatrics and Child Health and Children's Brain Tumour Research Centre
- Provide specialist support to families and children with brain tumours
- Roll out our programme of patient information events to new geographical locations
- Raise at least £100,000 from our gala Dorchester Fundraising Ball to fund additional research
- Secure an increase in grant income through the establishment of a trusts fundraising programme
- Provide support to and marketing of umbrella groups
- Improve communications and administration with our donors and supporters
- Develop our website to attract more beneficiaries and fundraisers

Research Plans

We remain at the forefront of brain tumour research and our research strategy will concentrate on the following areas:

- Funding our centre of excellence at UCL Cancer Institute
- Funding of project grants through our ongoing brain tumour research programme
- Funding and promotion of clinical trials in partnership with other institutions

Patient Support Plans

Our vision for patient support is to provide compassionate, flexible and practical support to ensure that every patient and family with a diagnosis gets access to the information and support that they need.

The patient support strategy will focus on the following areas:

- Development of a national telephone helpline
- Provision of information online and in treatment centres
- Information and outreach road shows across the UK
- Early diagnosis guidance

Statement of the Trustees Responsibilities

The trustees (who are also directors of the Samantha Dickson Brain Tumour Trust for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable for that period. In preparing these financial statements, the trustees are required to:

- Select suitable accounting policies and then apply them consistently;
- Observe the methods and principles in the Charities SORP;
- Make judgements and estimates that are reasonable and prudent;
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in business

The trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time of the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware; and
- The trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The report of the Trustees has been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

The financial statements were approved and authorised for issue by the Trustees on
and signed on their behalf by:

14th September
2010



Neil Dickson, Chair of Trustees

Independent Auditors Report to the Members of the Samantha Dickson Brain Tumour Trust

We have audited the financial statements of the Samantha Dickson Brain Tumour Trust for the year ended 31 March 2010 which comprise which comprise the Statement of Financial Activities, the Balance Sheet, and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and the requirements of the Financial Reporting Standard for Smaller Entities (effective April 2008).

This report is made solely to the charitable company's members, as a body, in accordance with Section 495 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and the charitable company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Respective responsibilities of Trustees and auditors

The Trustees', who are also the directors of the company for the purposes of company law, responsibilities for preparing the Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) and for being satisfied that the financial statements give a true and fair view are set out in the Statement of Trustees' Responsibilities.

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland).

We report to you our opinion as to whether the financial statements give a true and fair view, have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice, and have been prepared in accordance with the Companies Act 2006. We also report to you whether in our opinion the information given in the Trustees' Report is consistent with those financial statements. In addition we report to you if, in our opinion, the charitable company has not kept adequate accounting records, if the charitable company's financial statements are not in agreement with the accounting records and returns, if we have not received all the information and explanations we require for our audit, or if certain disclosures of trustees' remuneration specified by law are not made. We read the Trustees' Report and consider the implications for our report if we become aware of any apparent misstatements within it.

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis, of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgements made by the trustees in the preparation of the financial statements, and of whether the accounting policies are appropriate to the charitable company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of Information in the financial statements.

Opinion

In our opinion

- the financial statements give a true and fair view of the state of the charity's affairs as at 31 March 2010 and of its incoming resources and application of resources, including its income and expenditure, for the year then ended;
- the financial statements have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice applicable to Smaller Entities;
- the financial statements have been prepared in accordance with the Companies Act 2006; and
- the information given in the Trustees' Report is consistent with the financial statements.



.....

Bernie Watson (Senior Statutory Auditor)
for and on behalf of haysmacintyre, Statutory Auditor(s)

Fairfax House
15 Fulwood Place
London
WC1V 6AY

Dated 14 September 2010

**Samantha Dickson Brain Tumour Trust
Statement of Financial Activities
For the Year Ended 31 March 2010**

	Notes	Unrestricted Funds £	Restricted Funds £	Charity No. 1128354 Total 2010 £	Charity No. 1060627 Total 2009 £
<u>Income and Expenditure</u>					
Incoming Resources					
<i>Incoming resources from generated funds</i>					
Voluntary income	2	917,610	108,941	1,026,551	1,119,909
Activities for generating funds	3	63,377	3,814	67,191	56,423
Investment income		13,880	1,850	15,730	75,438
Grants receivable	4	-	300,898	300,898	53,144
Total Incoming Resources		994,867	415,503	1,410,370	1,304,914
Resources Expended					
<i>Costs of generating funds</i>					
Costs of generating voluntary income		263,925	208	264,133	290,874
<i>Charitable activities</i>					
Research costs		249,952	694,194	944,146	1,576,538
Patient support		145,091	44,341	189,432	157,842
<i>Governance costs</i>					
Management and administration	6	38,804	-	38,804	37,057
Total Resources Expended		697,772	738,743	1,436,515	2,062,311
(Expenditure)/Income before transfers		297,095	(323,240)	(26,145)	(757,397)
Net transfers between funds		(128,443)	128,443	-	-
Net (expenditure)/income after transfers		168,652	(194,797)	(26,145)	(757,397)
Reconciliation of Funds					
Balances at 1 April 2009		291,841	313,176	605,017	1,362,414
Balances at 31 March 2010		460,493	118,379	578,872	605,017


The Statement of Financial Activities includes all gains and losses recognised in the year.

All incoming resources and resources expended derive from continuing activities.
The notes on pages 14 to 22 form part of the financial statement

	Notes	£	Charity No. 1128354 2010 £	£	Charity No. 1060627 2009 £
Fixed Assets					
Tangible fixed assets	9		16,967		33,463
Current Assets					
Debtors	10	106,656		83,268	
Cash at bank		<u>1,805,001</u>		<u>1,682,944</u>	
		1,911,657		1,766,212	
Creditors:					
Amounts Falling Due Within One Year	11	<u>1,349,752</u>		<u>1,194,658</u>	
Net Current Assets			<u>561,905</u>		<u>571,554</u>
Total Assets Less Current Liabilities			<u><u>578,872</u></u>		<u><u>605,017</u></u>
Funds					
	15				
<i>Unrestricted Funds</i>					
General funds		456,769		291,841	
Designated funds		<u>3,724</u>		<u>-</u>	
			460,493		291,841
Restricted Funds		118,379	<u>118,379</u>		<u>313,176</u>
			<u><u>578,872</u></u>		<u><u>605,017</u></u>

The financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006 and in accordance with the Financial Reporting Standard for Smaller Entities (effective April 2008)

The financial statements were approved by the Trustees on 14th September 2010 and signed on their behalf by:



 Neil Dickson
 Chairman of Trustees

The notes on pages 14 to 22 form part of these financial statements.

Notes to the Financial Statements for the Year Ended 31 March 2010

1 Accounting Policies

(a) Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention. The financial statements have been prepared in accordance with the Statement of Recommended Practice "Accounting and Reporting by Charities" issued in March 2005, and in accordance with the Financial Reporting Standards for Smaller Entities (effective April 2008), applicable accounting standards and the Companies Act 2006.

Effective from 1 April 2009, the assets and undertaking relating to the Samantha Brain Dickson Tumour Trust, which had previously been held by the unincorporated charity registered in England and Wales numbered 1060627, were transferred to the charitable company. The financial statements includes notional comparatives relating to the old Charity as the entity as an organisation has not changed it's activities except for the incorporation of the Trust. This treatment reflects the fact that the circumstances described are merely a legal reorganisation of the charity whilst the Samantha Dickson Brain Tumour Trust has operated throughout under the control of the same trustees and with consistent charitable objectives.

(b) Company status

The company is a company limited by guarantee. The members of the company are the Trustees named on page 2. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

(c) Incoming Resources

All incoming resources are included in the Statement of Financial Activities when the company is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fund-raising events from private individuals and sponsors are taken into account on the basis of cash receipts. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest is accounted for on an accruals basis.

Where services and facilities are provided to the charity as a donation that would normally be purchased from our suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to the charity.

(d) Resources Expended

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent.

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010
Continued

Support costs are those costs incurred directly in support of expenditure in the objects of the Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling the Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the Trustees in the discharge of their statutory duties.

(e) **Stocks**

Stocks of publicity materials have been donated to the charity and have no carrying value at the balance sheet date.

(f) **Fund Accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by the Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to the appropriate fund.

(g) **Fixed assets**

The cost of tangible fixed assets is their purchase cost, together with incidental expenses of acquisition. Tangible fixed assets under £500 are not capitalised.

(h) **Depreciation**

Depreciation is charged on a straight-line basis at such a rate as will cause the assets to be written off in the books of the company at the end of their useful working life. The rates used are as follows:

Computer equipment	33%
Office equipment	20%

(i) **Donated Assets and Services**

Where services or assets are provided to the charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to the charity.

(j) **Operating Lease**

The charity classifies the lease of Saddlers House as an operating lease. Rental charges are charged on a straight line basis over the term of the lease (5 years).

(k) **Cash Flow**

The financial statements do not include a cash flow statement because the charitable company as a small reporting entity, is exempt from the requirement to prepare such a statement under the Financial Reporting Standard for Smaller Entities (effective April 2008).

(l) **Pensions**

The charitable company operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from the charity. Such contributions are held and administered completely independent of the charitable company's finances. The contributions are made by the charity and are accounted for on an accruals basis.

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010
Continued

2 Voluntary Income

	2010	2009
	£	£
Memorial donations	118,222	60,718
Merchandise	11,593	15,990
Donor marketing	19,352	38,388
Fundraising	393,462	245,757
Gift Aid	104,944	56,281
Trusts	189,190	56,775
Individual donations	189,788	608,772
	<u>1,026,551</u>	<u>1,082,681</u>

The changes to the income stream proportions between 2009 and 2010 are due to more sophisticated analysis.

3 Activities for Generating Funds

	2010	2009
	£	£
Events	67,191	93,471
	<u>67,191</u>	<u>93,471</u>

4 Grants receivable

	2010	2009
	£	£
GlaxoSmith Kline	148,966	5,000
Brian Cross Memorial Trust	64,566	-
BBC Children in Need	29,004	-
Lucy Savage	-	17,265
Childwick Trust	16,000	-
T & J Meyer Family Foundation	-	15,000
University of Nottingham/Health Foundation	12,267	-
Cancer Research UK	10,208	-
Others	19,887	15,879
	<u>300,898</u>	<u>53,144</u>

5 Analysis of Resources Expended

		Grants Payable	Direct Costs	Support Costs	Total 2010	Total 2009
		£	£	£	£	£
Fundraising		-	250,260	13,873	264,133	290,874
Research Costs	12a	757,724	136,833	49,589	944,146	1,576,538
Patient Support		-	179,483	9,949	189,432	157,842
Governance	6		36,766	2,038	38,804	37,057
		<u>757,724</u>	<u>603,342</u>	<u>75,449</u>	<u>1,436,515</u>	<u>2,062,311</u>

Support costs represent general office overheads such as staff costs, stationery, travel and telephone costs.

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010
Continued

Support Costs

	Research Costs £	Patient Support £	Fundraising £	Governance £	Total £
Rent, rates	18,620	3,736	5,209	765	28,330
PPS, Computer exp	13,033	2,615	3,647	535	19,830
Operating costs	5,880	1,180	1,645	242	8,947
Financial costs	10,842	2,176	3,033	444	16,495
Professional	1,214	242	339	52	1,847
	<u>49,589</u>	<u>9,949</u>	<u>13,873</u>	<u>2,038</u>	<u>75,449</u>

Where possible, these have been allocated directly to activities and remaining support costs have been attributed to different departments in proportion to the direct costs.

6 Governance Costs

	Total 2010 £	Total 2009 £
Auditors remuneration	7,708	13,750
Premises costs and insurances	2,064	1,396
Trustee meeting & recruitment advertising costs	8,835	3,906
Legal and professional	8,189	6,883
Support costs	2,038	1,509
Staff	9,969	9,613
	<u>38,803</u>	<u>37,057</u>

Trustees received no remuneration (2010: £nil) but one was reimbursed for expenses in the year (2010: £156), (2009: £220). The premium in respect of professional liability insurance covering trustee indemnity was £1,486 (2009: £1,396). Audit fees amounted to £6,300 plus VAT for the year (2009: £6,900 plus VAT).

7 Net Incoming/(Outgoing) Resources for the Year

	2010 £	2009 £
Auditors' remuneration	7,708	13,750
Depreciation	16,496	16,763
Pension costs	10,180	592

Auditors' remuneration in 2009 included combined charges for 2008 and 2009.

8 Staff costs

	2010 £	2009 £
The aggregate payroll costs of the above were:		
Wages and salaries	303,181	284,270
Social security costs	30,813	28,187
Pension	10,180	592
Other staff costs	26,144	-
	<u>370,318</u>	<u>313,049</u>

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010
Continued

The average number of full time equivalent employees during the year was as follows::

	2010	2009
Administrative staff	2	4
Direct staff	4	5
Marketing staff	4	2
Support staff	2	1
	<u>12</u>	<u>12</u>

No employee received remuneration amounting to more than £60,000 in either year.

9	<u>Tangible Fixed Assets</u>		Computer/Office Equipment £	
	Cost			
	At 1 April 2009		68,231	
	Additions			
	Disposals		-	
	At 31 March 2010		<u>68,231</u>	
	Depreciation			
	At 1 April 2009		34,768	
	Charge for period		16,496	
	Disposals		-	
	At 31 March 2010		<u>51,264</u>	
	Net Book Value			
	At 31 March 2010		<u>16,967</u>	
	At 31 March 2009		<u>33,463</u>	
10	<u>Debtors</u>			
		2010	2009	
		£	£	
	Gift Aid	41,029	39,185	
	Prepayments and accrued income	8,102	8,101	
	Other debtors	44,491	34,647	
	Debtors	13,034	1,335	
		<u>106,656</u>	<u>83,268</u>	
11	<u>Creditors: Amounts due within one year</u>	Notes		
		2010	2009	
		£	£	
	Grants Payable	12b	1,047,366	973,505
	Accruals		9,284	6,900
	Creditors		293,001	214,253
	Other Creditors		101	-
			<u>1,349,752</u>	<u>1,194,658</u>

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010
Continued

12 **Grants Payable**

	2010	2009
(a) The amount payable in the year comprises:	£	£
Bali Rooprai	-	100
Birmingham - Natalwala 9/48	-	1,000
Bristol - Frenchay - Dr. I. Wright 1/32	-	29,755
Institute of Neurology - Prof. S. Brandner 8/35	2,280	105,818
Institute of Neurology - Prof. S. Brandner 8/51	19,142	31,358
Institute of Neurology - Dr. T. Warr 8/34	(43,761)	64,693
Institute of Neurology - Dr. T. Warr 8/50	(9,676)	48,453
NCRI Project Officer	20,416	-
Queen Mary University of London - Prof. D. Sheer 4/43	65,291	96,866
Royal Marsden - Dr. N. Al-Saffar 6/54	81,462	75,147
UCL Centre of Excellence - Prof. P Salomoni 8/47	314,300	-
UCL Centre of Excellence - Dr S Pollard 8/105	21,051	-
University of Cambridge - Prof. V. P. Collins 10/29	(647)	44,744
University of Cambridge - Prof. V. P. Collins 10/36	(1,536)	52,937
University of Cambridge - Prof. V. P. Collins 10/106	48,345	-
University of Cambridge - Dr. K. Ichimura 10/33	(15,877)	68,608
University of Cambridge - Dr. H. Ring 10/45	41,700	53,407
University of Edinburgh - Dr. R Grant 11/52	(11,485)	60,000
University of Leeds - Prof. P. McKinney 13/42	7,530	33,267
University of Leicester CCLG 14/27	28,619	(28,619)
University of Leicester CCLG 14/28	(14,386)	40,586
University of Liverpool - Dr. V. See 15/37	-	79,071
University of Newcastle - Dr. S. Clifford 16/46	60,630	81,167
University of Newcastle - Dr. S. Clifford 16/49	-	44,107
University of Newcastle - Dr. S. Clifford 16/97	26,954	-
University of Nottingham - Dr. B. Coyle 17/38	-	42,398
University of Nottingham - Prof. R. Grundy 17/24	583	11,262
University of Nottingham - Prof. R. Grundy 17/31	52,691	45,911
University of Nottingham - Prof. R. Grundy 17/40	(743)	43,868
University of Nottingham - Prof. R. Grundy 17/53	57,768	66,192
University of Nottingham - Dr. P. Scotting 17/30	(18,108)	76,976
University of Nottingham - Prof D Walker 17/39	(11,046)	-
University of Southampton - Dr. C. Kennedy 20/23	2,297	19,095
University of Wolverhampton - Prof. J. Darling 21/22	(5,000)	5,000
University of Wolverhampton - Dr W Wang 21/44	38,930	94824
	<u>757,724</u>	<u>1,387,991</u>

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010
Continued

	2010	2009
	£	£
(b) Reconciliation of grants payable		
Commitments accrued at 1 April 2009	973,505	441,054
Grants payable for the year (net)	757,724	1,387,991
Grants paid during the year	(683,863)	(855,540)
Commitments accrued at 31 March 2010	<u>1,047,366</u>	<u>973,505</u>

(c) The total commitments authorised which are subject to the recipient fulfilling certain conditions but not accrued as expenditure were as follows:

	2010	2009
	£	£
University of Newcastle (Dr. S. Clifford) 16/46	-	65,687
University of Wolverhampton (Prof. J. Darling) 21/44	-	45,643
University of Nottingham (Prof. R. Grundy) 17/31	-	40,837
University of Nottingham (Dr. P. Scotting) 17/30	-	17,581
Queen Mary University of London (Prof. D. Sheer) 4/43	-	65,292
Institute of Neurology (Prof. S. Brandner) 8/51	-	51,500
University of Cambridge (Dr. H. Ring) 10/45	-	41,700
University of Nottingham (Prof. R. Grundy) 17/53	-	100,722
Royal Marsden (Dr. N. Al-Saffar) 6/54	-	168,238
University of Edinburgh (Dr. R. Grant) 11/52	-	120,000
Institute of Neurology (Prof. S. Brandner) 8/51	26,000	-
University of Cambridge (Dr. H. Ring) 10/45	-	-
University of Nottingham (Prof. R. Grundy) 17/53	43,857	-
Royal Marsden (Dr. N. Al-Saffar) 6/54	86,776	-
University of Edinburgh (Dr. R. Grant) 11/52	120,000	-
UCL Centre of Excellence - Prof. P Salomoni 8/47	959,278	-
UCL Centre of Excellence - Dr S Pollard 8/105	372,882	-
University of Cambridge - Prof. V. P. Collins 10/106	100,621	-
	<u>1,709,414</u>	<u>717,200</u>

Of this amount £643,011 (2009: £441,470) is due within one year.

13 Operating Lease Commitments

At 31 March 2010 the charity had annual commitments under non-cancellable leases as follows:

	2010	2009
	£	£
Expiry date		
Between two and five years	28,000	28,000
	<u>28,000</u>	<u>28,000</u>

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010
(Continued)

14	<u>Analysis of Net Assets Between Funds</u>	Unrestricted Funds	Restricted Funds	Total Funds 2010	Total Funds 2009	
		£	£	£	£	
	Tangible fixed assets	16,967	-	16,967	33,463	
	Debtors and accrued income	74,373	32,283	106,656	83,268	
	Cash at bank	670,273	1,134,728	1,805,001	1,682,944	
	Creditors and accrued expenses	(301,120)	(1,048,632)	(1,349,752)	(1,194,658)	
		<u>460,493</u>	<u>118,379</u>	<u>578,872</u>	<u>605,017</u>	
15	<u>Funds</u>	Balance at 01.04.09 £	Incoming Resources £	Resources Expended £	Transfers £	Balance at 31.03.10 £
	Restricted Funds					
	GlaxoSmith Kline	-	148,966	(48,345)	-	100,621
	Astro Fund Support	1,057	7	-	-	1,064
	Support Group	15,801	4,155	(13,071)	-	6,885
	Ocean FM	-	938	(938)	-	-
	UCL Fund	27,379	5,010	(32,389)	-	-
	Childwick Trust	-	16,000	(16,000)	-	-
	Brian Cross MemorialTrust	-	64,566	(64,566)	-	-
	Daisy Trust	1,000	-	(1,000)	-	-
	Toy & Hobby Trust	-	2,637	(328)	-	2,309
	Oligodendroglioma Research Fund	-	1,005	(1,005)	-	-
	Broyst Foundation	-	2,500	-	-	2,500
	C Charitable Trust	-	5,000	-	-	5,000
	BBC Children in Need	-	29,004	(29,004)	-	-
	Peter Culverhouse Memorial Trust	-	4,307	(4,307)	-	-
	Clowns in the Sky	-	3,500	(3,500)	-	-
	Umbrella Group Research Fund	267,939	105,433	(501,815)	128,443	-
	Cancer Research UK	-	10,208	(10,208)	-	-
	University of Nottingham	-	12,267	(12,267)	-	-
		<u>313,176</u>	<u>415,503</u>	<u>(738,743)</u>	<u>128,443</u>	<u>118,379</u>
	Unrestricted Funds					
	General Fund	291,841	994,867	(687,496)	(142,443)	456,769
	Designated Fund	-	-	(10,276)	14,000	3,724
		<u>605,017</u>	<u>1,410,370</u>	<u>(1,436,515)</u>	<u>-</u>	<u>578,872</u>

In the year the Trustees restricted funds of £128,443 for research projects and also designated £14,000 to fund brain tumour information days across the UK.

Samantha Dickson Brain Tumour Trust
Annual Report and Financial Statements for the Year Ended 31 March 2010
(Continued)

Restricted Funds

Fund	Purpose and restriction in use
GlaxoSmith Kline	To fund a research project at Cambridge University
Astro Fund Support Support Group	To fund support in particular where this relates to low grade tumours
Ocean FM	To fund patient support
UCL Fund	To fund a day out for children with brain tumours
Childwick Trust	To fund SDBTT/UCL Centre of Excellence
Brian Cross Memorial Trust	To fund an early diagnosis project
Daisy Trust	To fund SDBTT/UCL Centre of Excellence
British Toy & Hobby Trust	To fund an information day in London
Oligodendroglioma Research	To fund a day out for children with brain tumours
Broyst Foundation	To fund research into oligodendroglioma tumours
C Charitable Trust	To fund an information day in the south
BBC Children in Need	To fund telephone helpline and information service
Peter Culverhouse Memorial Trust	To fund a telephone helpline and information worker
Clowns in the Sky	To fund low grade glioma research
Umbrella Group Research Fund	To fund increasing quality of life after treatment
	To fund brain tumour research

Designated Funds

Designated funds are unrestricted funds earmarked by the Trustees for the payment of research grants and/or patient support costs due in less than one year.

Unrestricted Funds

In the absence of restrictions placed on income by donors, the trustees utilise funds to support the long-term foundations of the charity and its income requirements. A transfer was made from unrestricted to restricted funds to cover the research commitments. A further transfer was made to designated funds for patient support information days.

16 Pension Commitment

The charitable company operates a defined contribution scheme administered by Scottish Equitable Plc. The pension cost charges represents contributions made by the charity amounted to £10,810 (2009: £592). As at 31st March 2010, £101 (2009: £133) is included in liabilities.